2486 Dunwin Drive
133 articles with Acerus Pharma
Acerus Announces Launch of NATESTO ® Specialty Sales Team in the United States Initially 22 in Size, Dedicated Staff to Target Urologists and Endocrinologists TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product,
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing lice
Acerus Announces Significant Improvement in NATESTO ® Insurance Coverage in the United States NATESTO ® now covered as a Preferred Brand by leading national pharmacy benefits manager TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., on
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2020 (“Q1-2020). Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1-2020 Highlights Refinancing transactions provide $18 million of new capital to suppor
Acerus Pharmaceuticals Corporation announced that Norma Beauchamp has resigned as a member of the Company's Board of Directors.
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Dr. Geoff Cotton, MB BS, MBA to its Board of Directors. Dr. Cotton is a healthcare executive, venture capital adviser, and angel investor with 20 years experience in the pharmaceutical industry. He spent over 17 years with Gilead Sciences Inc. in Medical Affairs and Commercial roles of increasing responsibility culminating in leadership of the Glo
Acerus Announces Publication of Results for NATESTO ® Spermatogenesis Study in Journal of Urology
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its avanafil New Drug Submission (NDS). Health Canada has requested the provision of additional quality information related to the avanafil drug substance in alignment with Intern
Acerus Pharmaceuticals Corporation issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic.
Acerus Pharmaceuticals Corporation will announce financial results for the three and twelve month periods ending December 31, 2019 on Wednesday, March 4, 2020 before the market opens.
Acerus Completes Refinancing Transactions Including US$18,000,000 in Gross Proceeds From New Equity Financing
Feb. 21, 2020 14:55 UTC TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) is pleased to announce today’s closing of the refinancing transactions previously announced on February 12, 2020 (the “Refinancing Transactions”). Acerus received US$18,000,000 in gross proceeds from the private placement of 449,148,891 common shares of the Company (the “Common Shares”) to First Generation Capital Inc. (“First Generation”) and
Acerus Pharmaceuticals Corporation announced that it has entered into agreements with First Generation Capital, Inc. in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC in respect of an amendment to the Company’s existing credit facility with SWK.
Acerus Announces Acceptance of Two NATESTO® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program
Feb. 5, 2020 13:30 UTC Acerus Announces Acceptance of Two NATESTO ® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO ® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program.
Acerus Pharmaceuticals Corporation announced the acceptance of a scientific abstract reporting the results of the NATESTO® Spermatogenesis Study by the Endocrine Society for presentation at their Annual Meeting.
Acerus Pharmaceuticals Corporation announced that the dossier filed as a Decentralized Procedure in 19 European countries for the approval of NATESTO® has been withdrawn.
Acerus Announces Amendment to Credit Agreement, Waiver of Certain Q4 Financial Covenants and Upcoming Additional Financing From First Generation Capital
The nature of the amendment is to set the minimum threshold for Consolidated Unencumbered Liquid Assets required to be maintained by the Company.
Expanded U.S. NATETSO® Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational
Closing conditions waived - Amended & Restated Partnership Agreement is now closed
Acerus Pharmaceuticals Corporation reported its financial results for the three- and nine-month period ended September 30, 2019.
The company will also host a conference call on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time.
Acerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
Acerus Pharmaceuticals Corporation announced it will host a Key Opinion Leader meeting on new, unique clinical evidence supporting the expanded use of NATESTO® for the treatment of hypogonadism on Wednesday, October 30th in New York City.